Cargando…
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
Despite increasingly successful treatment of pediatric ALL, up to 20% of patients encounter relapse. By current biomarkers, the majority of relapse patients is initially not identified indicating the need for prognostic and therapeutic targets reflecting leukemia biology. We previously described tha...
Autores principales: | Hasan, Md. Nabiul, Queudeville, Manon, Trentin, Luca, Eckhoff, Sarah Mirjam, Bronzini, Ilaria, Palmi, Chiara, Barth, Thomas, Cazzaniga, Giovanni, te Kronnie, Geertruy, Debatin, Klaus-Michael, Meyer, Lüder Hinrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359301/ https://www.ncbi.nlm.nih.gov/pubmed/25682198 |
Ejemplares similares
-
Characterization and identification of leukemia initiating cells in pediatric acute lymphoblastic leukemia
por: Trentin, Luca, et al.
Publicado: (2014) -
Overcoming apoptosis resistance in high risk acute lymphoblastic leukemia by SMAC mimetics in a preclinical ALL xenograft model in vivo
por: Schirmer, Melanie, et al.
Publicado: (2014) -
Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state
por: Trentin, Luca, et al.
Publicado: (2018) -
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
por: Demir, Salih, et al.
Publicado: (2020) -
Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia
por: Schirmer, M, et al.
Publicado: (2016)